The Role of 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in the Diagnosis of Lewy Body Disease in Patients with Dementia in a Memory Clinic
Authors:
- Haruo HanyuHHHaruo Hanyu
- Soichiro ShimizuSSSoichiro Shimizu
- Kentaro HiraoKHKentaro Hirao
- Hirofumi SakuraiHSHirofumi Sakurai
- Toshihiko IwamotoTIToshihiko Iwamoto
- Taishiro ChikamoriTCTaishiro Chikamori
- Satoshi HidaSHSatoshi Hida
- Akira YamashinaAYAkira Yamashina
- Kiyoshi KoizumiKKKiyoshi Koizumi
- Kimihiko AbeKAKimihiko Abe
- 1 November 2006
- journal article
- research article
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 22 (5-6) , 379-384
Abstract
Reduction in cardiac 123I-metaiodobenzylguanidine (MIBG) uptake is a characteristic feature of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), and is useful in distinguishing them from other neurodegenerative disorders. The aim of this study was to investigate the role of this method of scintigraphy in the differential diagnosis of dementia in our Memory Clinic. We performed MIBG scintigraphy in patients with dementia referred to the Memory Clinic and compared the heart-to-mediastinum (H/M) ratio of MIBG uptake. Thirty out of 32 patients with DLB and all 9 PD with dementia patients had reduced H/M ratios, whereas 37 out of 40 patients with Alzheimer’s disease had normal H/M ratios. Most patients with vascular dementia, frontotemporal dementia, and other dementias had normal H/M ratios. The overall sensitivity to positively identify patients with Lewy body disease (including DLB and PD with dementia) was 95%, and the specificity to distinguish them from patients with other types of dementias was 87%. MIBG scintigraphy showed a high sensitivity for the detection of Lewy body disease, and also a high specificity for discrimination from other types of dementia. The scintigraphy may provide a valuable and adjunctive method in the diagnosis of Lewy body disease and a differential diagnostic tool for patients with dementias.Keywords
This publication has 36 references indexed in Scilit:
- Differences in magnetization transfer ratios of the hippocampus between dementia with Lewy bodies and Alzheimer's diseaseNeuroscience Letters, 2005
- Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2005
- The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's diseaseNeuroImage, 2004
- Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's diseaseMovement Disorders, 2003
- [123I] Meta-iodobenzylguanidine Myocardial Scintigraphy Differentiates Corticohasal Degeneration from Parkinson's Disease.Internal Medicine, 2003
- Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese populationPsychiatry and Clinical Neurosciences, 2001
- Clinical Diagnosis of Dementia with Lewy Bodies in a Japanese Dementia RegistryDementia and Geriatric Cognitive Disorders, 1999
- A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG)Nuclear Medicine Communications, 1992
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- “Mini-mental state”Journal of Psychiatric Research, 1975